Rosen Quoted on New Safety Threats with Approved Drugs

09 May 2017 Modern Healthcare News
Partner David Rosen was quoted in a Modern Healthcare article, “New Safety Threats Identified in One-Third of Drugs Post-Approval,” covering why these statistics make sense, and covering FDA user fees as they relate to the issue.

Rosen explained he doesn’t think “the user fee time deadlines really have an impact [on the issue]; it doesn’t mean that the FDA is putting out drugs that are less safe. The FDA takes safety very seriously and does the best job it can in making sure labels show the proper risk and benefits and are updated.”

Related Services

Insights

State of Michigan Election, COVID-19, and Budget Update
22 October 2020
2020 Election Resource Center
AI Podcast Series, Episode 1: Setting the Stage with Technology Risk Expert Ken DeJarnette – Part One
21 October 2020
Privacy, Cybersecurity & Technology Law Perspectives
ERISA/Cybersecurity Considerations in the COVID Age
21 October 2020
Privacy, Cybersecurity & Technology Law Perspectives
A Review of Recent Whistleblower Developments
21 October 2020
Legal News: Whistleblower Developments